USD10
NBP Shares
About NovaBridge BiosciencesNovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
USD10
NBP Shares
About NovaBridge BiosciencesNovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$213.95M
OPEN PRICE
$1.76
LOW (1Y)
$1.46
HIGH (1Y)
$6.79
LOW (24H)
$1.74
HIGH (24H)
$1.83
VOLUME (24H)
$217.54K
17.58%
Price history
Time | Price | Change |
|---|---|---|
Today | $1.76 | |
1 Day | $1.79 | |
1 Week | $1.94 | |
1 Month | $1.55 | |
1 Year | $2.12 |
Past performance is not a reliable indicator of future results.
Discover more
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.